Aristea Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (2018)

Organization Overview

First Clinical Trial
2019
NCT03988335
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Aristea Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

rist4721 (5 trials)

Drugs in Phase 1 Trials (1)

rist4271 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blister (Phase 1)

Psoriasis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 2